Seres dou­bles down on a mi­cro­bio­me do-over as the FDA clears a make-or-break study

Seres CEO Roger Pomer­antz says he’s back on track.

Eight months af­ter the biotech in­dus­try’s lead­ing mi­cro­bio­me pro­gram de­railed in a dis­as­trous Phase II, Seres …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER